FILE - In this July 8, 2016, file photo, a pharmacist holds a package of EpiPens epinephrine auto-injector, a Mylan product, in Sacramento, Calif. Mylan CEO Heather Bresch is defending the cost for life-saving EpiPens and is offering no suggestion that there are plans to lower prices. Bresch’s prepared testimony was released by the House Oversight and Government Reform Committee ahead of her Sept. 21 appearance before the panel. (AP Photo/Rich Pedroncelli, File)

FILE - In this July 8, 2016, file photo, a pharmacist holds a package of EpiPens epinephrine auto-injector, a Mylan product, in Sacramento, Calif. Mylan CEO Heather Bresch is defending the cost for life-saving EpiPens and is offering no suggestion ... that there are plans to lower prices. Bresch’s prepared testimony was released by the House Oversight and Government Reform Committee ahead of her Sept. 21 appearance before the panel. (AP Photo/Rich Pedroncelli, File) (The Associated Press)

Mylan CEO defends EpiPen prices

Markets Associated Press

Mylan CEO Heather Bresch is defending the cost for life-saving EpiPens and is offering no suggestion that there are plans to lower prices.

Continue Reading Below

Bresch's prepared testimony was released by the House Oversight and Government Reform Committee ahead of her Wednesday appearance before the panel.

The price of EpiPens has grown to $608 for a two-pack, an increase of more than 500 percent since 2007. The Republican chairman of the House Oversight and Government Reform Committee has said there is "justified outrage" from families struggling to pay for the emergency allergy shots.

Bresch says in the testimony that she wishes the company had "better anticipated the magnitude and acceleration" of the rising prices for some families. But she says investments are necessary to ensure more access for those who need it.